Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Cancer Biomarker Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size of cancer biomarkers has witnessed considerable expansion in recent years, growing from $22.19 billion in 2024 and projected to reach $25.09 billion in 2025. This significant increase at a compound annual growth rate (CAGR) of 13.1% can be correlated to various factors. They include the transition towards personalized medicine, the advent of immunotherapy innovations, the evolution of the regulatory framework, combined research initiatives, and an increased focus on non-coding RNAs.
In the upcoming years, the cancer biomarker market is forecasted to experience swift expansion, escalating up to $45.33 billion by 2029, with a CAGR of 15.9%. The expected growth during the forecast period can be associated with the transition towards patient-oriented diagnostics, the inclusion of biomarkers in clinical studies, the development of multi-biomarker panels, exploration of non-coding RNAs and the bringing of biomarker tests to market. The period also anticipates advancements in sectors such as genomics, precision medicine strategies, liquid biopsies, advances in immunotherapy, and integration of artificial intelligence.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theCancer Biomarker Market?
The increasing occurrence of cancer is propelling the expansion of the cancer biomarker market. The cancer frequency rate refers to the amount of new cancers of a particular location/type that arise in a particular population within a certain year, it is presented as cancers per 100,000 individuals at risk. The rising prevalence of cancer is promoting the extensive utilization of cancer biomarkers given their importance in determining disease risk, screening for hidden primary tumors, identifying benign from malignant signs, or differentiating between various forms of malignancy. For example, in January 2022, the American Cancer Society, a health organization based in the US, published research indicating an anticipation of 609,360 cancer deaths and 1.9 million new instances of cancer in 2022. This equates to approximately 1,670 fatalities on a daily basis. Consequently, the increasing occurrence of cancer will likely accelerate the expansion of the cancer biomarker market in the forthcoming years.
Which Segments in the Cancer Biomarker Offer the Most Growth?
The cancer biomarkermarket covered in this report is segmented –
1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
Subsegments:
1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein
2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles
3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp
What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theCancer Biomarker Market?# Market?
North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Current Market Growth and Trends in the Cancer Biomarker Industry?
Key market players in the cancer biomarker sector are concentrating on the creation of inventive solutions, such as AI-enabled cancer biomarkers, to improve diagnostic precision and create tailored treatment strategies for individuals. AI-powered cancer biomarkers denote biological cancer signals that are detected and investigated using artificial intelligence mechanisms. For example, in September 2023, Ibex Medical Analytics, an American company, introduced Galen Breast HER2, an AI-supported solution engineered to boost the reliability and repeatability of HER2 grading in breast cancer patients. This groundbreaking platform supports pathologists by auto-detecting invasive tumor regions and quantifying HER2 expression in alignment with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system employs an innovative computational process to scrutinize immunohistochemistry (IHC)-stained slides, offering detailed imagery of staining patterns and empowering pathologists to make insightful treatment choices.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
What Are the Key Elements That Define the Cancer Biomarker Market?
A cancer biomarker refers to a biological molecule present in the blood, tissues, or other bodily fluids, that indicates the presence of normal or abnormal activity, as well as a condition or disease. Cancer biomarkers are used to characterize alterations in the tumor.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model